Rinucumab

Monoclonal antibody

IdentifiersCAS Number

ChemSpider

UNII

Chemical and physical dataFormulaC₆₄₇₂H₉₉₇₄N₁₇₁₀O₂₀₂₂S₃₈Molar mass145309.21 g·mol⁻¹

Rinucumab (REGN2176) is a monoclonal antibody designed for the treatment of neovascular age-related macular degeneration.^[1]^[2]

This drug was developed by Regeneron Pharmaceuticals, Inc.

References

^ "Rinucumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
^ Hussain RM, Ciulla TA (September 2017). "Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration". Expert Opinion on Emerging Drugs. 22 (3): 235–246. doi:10.1080/14728214.2017.1362390. PMID 28756707. S2CID 3505145.

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone

Human	Burosumab Denosumab
Humanized	Blosozumab^† Romosozumab

Musculoskeletal

Human	Stamulumab^†

Circulatory

Human	Abelacimab Alirocumab Ascrinvacumab^§ Bentracimab^† Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Nesvacumab Orticumab Ramucirumab Rinucumab
Mouse	Biciromab^‡ Imciromab^‡
Chimeric	Abciximab Volociximab
Humanized	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Demcizumab Emicizumab Etaracizumab Faricimab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Human	Anti-amyloid drugs Aducanumab Donanemab Gantenerumab^† Lecanemab Erenumab Fasinumab^† Fulranumab Opicinumab
Humanized	Bapineuzumab^† Crenezumab^† Eptinezumab Fremanezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Semorinemab Solanezumab Tanezumab^†